Type i interferons: Ancient peptides with still under-discovered anti-cancer properties

Protein and Peptide Letters

Volumn 20, Issue 4, 2013, Pages 412-423

  Caraglia, Michele ^a   Dicitore, Alessandra ^b   Marra, Monica ^a   Castiglioni, Sara ^b   Persani, Luca ^b,c   Sperlongano, Pasquale ^a   Tagliaferri, Pierosandro ^d   Abbruzzese, Alberto ^a   Vitale, Giovanni ^b,c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Egf p; Farnesyltransferase inhibitors; Interferon alpha; Interferon beta; Mtor; Pegylated interferons; Stats; Type i interferons

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GEFITINIB; IMATINIB; INTERFERON; NATALIZUMAB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; STAT PROTEIN; TIPIFARNIB;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; BIOLOGICAL ACTIVITY; BONE MARROW SUPPRESSION; CELL CYCLE ARREST; CHRONIC MYELOID LEUKEMIA; COGNITIVE DEFECT; CUTANEOUS MELANOMA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEPATITIS C; HERPES VIRUS INFECTION; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; METASTASIS; MOOD DISORDER; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PSYCHOPATHY; RIGOR; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; APOPTOSIS; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION;

EID: 84877959168     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986613805290372     Document Type: Article

References (124)

1. Vitale, G.; Caraglia, M.; van Koetsveld, P.M.; Maroni, P.; Marra, M.; Colao, A.; Lamberts, S.W.; Cavagnini, F.; Hofland, L.J. Potential role of type I interferons in the treatment of pituitary adenomas. Rev. Endocr. Metab. Disord., 2009, 10(2), 125-133.
2. Steen HC, Gamero AM. Interferon-lambda as a potential therapeutic agent in cancer treatment. J. Interferon Cytokine Res., 2010, 30(8), 597-602.
3. Nagano, Y.; Kojima, Y. Pouvoir immunisant du virus vaccinal inactiv par des rayons ultraviolets. C. R. Seances Soc. Biol. Fil., 1954, 148(19-20), 1700-1702.
4. Isaacs, A.; Lindenmann, J. Virus interference: the interferon. Proc. R. Soc. Med., 1957, 147, 258-267.
5. Gresser, I. Production of interferon by suspensions of human leucocytes. Proc. Soc. Exp. Biol. Med., 1961, 108, 799-803.
6. Rubinstein, M.; Rubinstein, S.; Familletti, P.C.; Gross, M.S.; Miller, R.S.; Waldman, A.A.; Pestka, S. Human leukocyte interferon purified to homogeneity. Science, 1978, 202, 1289-1290.
7. Taniguchi, T.; Fujii-Kuriyama, Y.; Muramatsu, M. Molecular cloning of human interferon cDNA. PNAS, 1980, 77(7), 4003-4006.
8. Pestka, S. Cloning of the human interferons. Methods Enzymol., 1981, 78, 1-632.
9. Nagata, S.; Mantei, N.; Weissmann, C. The structure of one of the eight or more distinct chromosomal genes for human interferonalpha. Nature, 1980, 287(5781), 401-408.
10. Gray, P.W.; Goeddel, D.V. Structure of the human immune interferon gene. Nature, 1980, 298(5877), 859-863.
11. Pestka, S. Interferons. Part B. Introduction. Methods Enzymol., 1981, 79, 1-677.
12. Pestka, S. Interferon: a decade of accomplishments, foundations of the future in research and therapy. Methods Enzymol., 1986, 119, 1-845.
13. Pestka, S. The human interferon alpha species and receptors. Biopolymers, 2000, 55, 254-287.
14. Nagata, S.; Taira, H.; Hall, A.; Johnsrud, L.; Streuli, M.; Ecsdi, J.; Boll, W.; Cantell, K.; Weissmann, C. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature, 1980, 284(5754), 316-320.
15. Spiegel, R.J. Intron A (Interferon Alfa-2B): clinical overview and future directions. Semin. Oncol., 1986, 13(2), 89-101.
16. Pham, P.; Pharm D. Profiles on New Drugs Peg-interferon 2b (Peg- Intron(R). Infect. Dis. Clin. Pract., 2001, 10(5), 281.
17. Iafolla, M. Pegasys: FDA approved Pegasys (peginterferon alfa-2a) for the treatment of hepatitis C. Sidahora, 2002, 4, 8-10.
18. Finter, N.B. Cytokines in the treatment of virus infections. Biotherapy, 1994, 7(3-4), 151-159.
19. Borden, E.C.; Sen, G.C.; Uze, G.; Silverman, R.H.; Ransohoff, R.M.; Foster, G.R.; Stark, G.R. Interferons at age 50, past, current and future impact on biomedicine. Nat. Rev. Drug Discov., 2007, 6, 975-990.
20. Bekisz, J.; Schmeisser, H.; Hernandez, J.; Goldman, N. D.; Zoon; K. C. Human interferons alpha, beta and omega. Growth Fact. 2004, 22, 243-251.
21. Pestka, S. Interferons, interferon-like cytokines and their receptors. Immunol. Rev., 2004, 202, 8-32.
22. Bazan, J.F. Shared architecture of hormone binding domains in type I and II interferon receptors. Cell., 1990, 61(5), 753-754.
23. Thoreau, E.; Petridou, B.; Kelly P.A.; Djiane, J.; Mornon, J.P. Structural symmetry of the extracellular domain of the cytokine/ growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis. FEBS Lett., 1991, 282(1), 26-31.
24. De Maeyer, E.; De Maeyer-Guignard, J. Type I interferons. Int.Rev. Immunol., 1998, 17, 53-73.
25. Pestka, S. The interferon receptors. Semin. Oncol., 1997, 24, S9- 18-S9-40.
26. Sadowski, H.B.; Shuai, K.; Darnell, J.E. Jr.; Gilman, M.Z. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science, 1993, 261, 1739-1744.
27. Shuai, K.; Stark, G.R.; Kerr I.M.; Darnell J.E. Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferongamma. Science, 1993, 261, 1744-1746.
28. Darnell, J.E. Jr.; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signalling proteins. Science, 1994, 264, 1415-1421.
29. Copeland, N.G.; Gilbert, D.J.; Schindler, C,; Zhong, Z.; Wen, Z.; Darnell, J.E. Jr.; Mui A.L.; Miyajima, A.; Quelle, F.W.; Ihle, J.N.Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics, 1995, 29, 225-228.
30. Shuai, K.; Horvath C.M.; Huang, L.H.T.; Qureshi S.A.; Cowburn, D.; Darnell J.E. Jr. Interferon activation of the transcription factor Stat91 involves dimerization through SH2- phosphotyrosyl peptide interactions. Cell, 1994, 76, 821-828.
31. Prejean, C.; Colamonici, O.R.Role of the cytoplasmic domains of the type I interferon receptor subunits in signaling. Semin. Cancer Biol., 2000, 10(2), 83-92.
32. Vinkemeier, U.; Cohen, S.L.; Moarefi, I.; Chait, B.T.; Kuriyan, J.; Darnell, J.E. Jr. DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J., 1996, 15, 5616-5626.
33. Horvath, C.M.; Wen, Z.; Darnell, J.E.A STAT protein domain that determines DNA sequence recognition suggests a novel DNAbinding domain. Genes. Dev., 1995, 9, 984-994.
34. Leonard, W.J.; OShea, J.J. Jaks and STATs: biological implications. Annu. Rev. Immunol., 1998, 16, 293-322.
35. Zhang, X.; Blenis, J.; Li, H.C.; Schindler, C.; Chen-Kiang, S. Requirement of serine phosphorylation for formation of STATpromoter complexes. Science, 1995, 267, 1990-1994.
36. Wen, Z.; Zhong, Z.; Darnell, J.E. Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell, 1995, 82, 241-250.
37. Turkson, J.; Bowman, T.; Adnane, J.; Zhang, Y.; Djeu, J.Y.; Sekharam, M.; Frank, D.A.; Holzman, L.B.; Wu, J.; Sebti, S.; Jove, R. Requirement for Ras=Rac1- mediated p38 and c- Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol. Cell. Biol., 1999, 19, 7519-7528.
38. Bromberg, J.F.; Horvath, C.M.; Besser, D.; Lathem, W.W.; Darnell, J.E. Jr.Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol., 1998, 18, 2553-2558.
39. Caraglia, M.; Marra, M.; Tagliaferro, P.; Lamberts, S.W.; Zappavigna, S.; Misso, G; Cavagnini, F.; Facchini, G.; Abruzzese, A.; Hofland, L.J.; Vitale, G. Emerging strategies to strengthen the antitumour activity of type I interferons: overcoming survival pathways. Curr. Cancer. Drug. Targets, 2009, 9(5), 690-704.
40. Meinke, A.; Barahmand-Pour, F.; Wohrl, S.; Stoiber, D.; Decker, T. Activation of different Stat5 isoforms contributes to cell typerestricted signaling in response to interferons. Mol.Cell. Biol., 1996, 16, 6937-6945.
41. Vitale, G.; van Eijck, C.H.; van Koetsveld, P.M.; Erdmann, J.J.; Speel, E.J.; van der Wansem Ing, K.; Mooij, D.M.; Colao, A.; Lombardi, G.; Croze, E.; Lamberts, S.W., Hofland, L.J. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann. Surg., 2007, 246, 259-68.
42. Vitale, G.; de Herder, W.W.; va Koetsveld, P.M.; Waaijers, M., Schoordijk, W.; Croze, E., Colao, A.; Lamberts, S.W.; Hofland, L.J. Interferon-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer. Res., 2006, 66, 554-562.
43. Vitale, G.; van Koetsveld, P.M.; de Herder, W.W.; van der Wansem, K.; Janssen, J.A., Colao, A.; Lombardi, G.; Lamberts, S.W.; Hofland, L.J. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am. J. Physiol. Endocrinol. Metab., 2009, 296(3), 559-566.
44. van Koetsveld, P.M; Vitale, G.; de Herder, W.W.; Feelders, R.A.; van der Wansem, K.; Waaijers, M.; van Eijck, C.H.; Speel, E.J.; Croze, E.; van der Lely, A.J.; Lamberts, S.W.; Hofland, L.J. Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J. Clin. Endocrinol. Metab., 2006, 91, 4537-4543.
45. Johns, T.G.; Mackay, I.R.; Callister, K.A.; Hertzog, P.J.; Devenish, R.J., Linnane, A.W. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J. Nat.l Cancer. Inst., 1992, 84, 1185-1190.
46. Caraglia, M.; Budillon, A., Vitale, G., Lupoli, G., Tagliaferri, P., Abbruzzese, A. Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. Eur. J. Biochem., 2000, 267, 3919-3936.
47. Datta, B.; Datta, R. Induction of apoptosis due to lowering the level of eukaryotic initiation factor 2-associated protein, p67, from mammalian cells by antisense approach. Exp. Cell Res., 1999, 246, 376-383.
48. Chong, K.L.; Feng, L.; Schappert, K.; Meurs, E.; Donahue, T.F.; Friesen, J.D.; Hovanessian, A.G.; Williams, B.R. Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. EMBO J., 1992, 11, 1553-1562.
49. Petryshyn, R.; Chen, J.J.; London, I.M. Growth-related expression of a double- stranded RNA-dependent protein kinase in 3T3 cells. J. Biol. Chem., 1984, 259, 14736-14742.
50. Meurs, E.; Galabru, J.; Barber, G.N.; Katze, M.G.; Hovanessian, A. G. Tumor suppressor function of the interferon-induced double stranded RNA-activated protein kinase. PNAS, 1993, 90, 232-236.
51. Gil, J.; Esteban, M. Induction of apoptosis by the dsRNA dependent protein kinase (PKR), mechanism of action. Apoptosis, 2000, 5, 107-114.
52. Caraglia, M.; Passeggio, A.; Beninati, S.; Leardi, A.; Nicolini, L.; Improta, S.; Pinto, A.; Bianco, A.R.; Tagliaferri, P.; Abbruzzese, A. Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. Biochem. J., 1997, 324, 737-741.
53. Abbruzzese, A; Park, M.H.; Folk, J.E. Deoxyhypusine hydroxylase from rat estis. Partial purification and characterization. J. Biol. Chem., 1986, 261, 3085-3089.
54. Park, M.H.; Wolff, E.C.; Smit-McBride, Z.; Hershey, J.W.B.; Folk, J.E. Comparison of the activities of variant forms of eIF-4D. The requirement for hypusine or deoxyhypusine. J. Biol. Chem., 1991, 266, 7988-7994.
55. Kaur, S.; Katsoulidis, E.; Platanias, L.C. Akt and mRNA translation by interferons. Cell Cycle, 2008, 7(14), 2112-2116.
56. Kroczynska, B.; Kaur, S., Platanias, L.C. Growth suppressive cytokines and the AKT/mTOR pathway. Cytokine, 2009, 48, 138-143.
57. Adams, J. The proteasome, structure, function, and role in the cell. Cancer Treat. Rev., 2003, 29, 3-9.
58. Austin, K.J.; Ward, S.K.; Teixeira, M.G.; Dean, V.C.; Moore, D.W.; Hansen, T.R. Ubiquitin cross-reactive protein is released by the bovine uterus in response to interferon during early pregnancy. Biol. Reprod., 1996, 54, 600-606.
59. Nyman, T.A; Matikainen, S.; Sareneva, T.; Julkunen, I.; Kalkkinen, N. Proteome analysis reveals ubiquitin-conjugating enzymes to be a new family of interferon-alpha-regulated genes. Eur. J. Biochem., 2000, 267, 4011-4019.
60. Esposito, C.; Marra, M.; Giuberti, G.; D'Alessandro, A. M.; Porta, R.; Cozzolino, A.; Caraglia, M.; Abbruzzese, A. Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells. Biochem. J., 2003, 370, 205-212.
61. Spets, H.; Georgii-Hemming, P.; Siljason, J.; Nilsson, K.; Jernberg- Wiklund, H. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)- dependent and IL-6-independent multiple myeloma cell lines. Blood, 1998, 92, 2914-2923.
62. Roth, W.; Wagenknecht, B.; Dichgans, J.; Weller, M. Interferonalpha enhances CD95L-induced apoptosis of human malignant glioma cells. J. Neuroimmunol., 1998, 87, 121-129.
63. Buechner, S.A.; Wernli, M.; Harr, T.; Hahn, S.; Itin, P.; Erb, P. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J. Clin. Investig., 1997, 100, 2691-2696.
64. Chawla-Sarkar, M.; Leaman, D.W.; Borden, E.C. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2, correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin. Cancer Res., 2001, 7, 1821-1831.
65. Sanceau, J.; Hiscott, J.; Delattre, O.; Wietzerbin, J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene, 2000, 19, 3372-3383.
66. Selleri, C.; Sato, T., Del Vecchio, L.; Luciano, L., Barrett, A.J.; Rotoli, B., Young, N.S.; Maciejewski, J.P. Involvement of Fasmediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood, 1997, 89(3), 957-964.
67. Gmez-Benito, M.; Balsas, P., Carvajal-Vergara, X.; Pandiella, A.; Anel, A.; Marzo, I.; Naval, J. Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. Cell Signal., 2007, 19(4), 844-854.
68. Xing, Z., Harper, R., Anunciacion, J., Yang, Z.; Gao, W.; Qu, B.; Guan, Y.; Cardona, C.J. Host immune and apoptotic responses to avian influenza virus H9N2 in human tracheobronchial epithelial cells. Am. J. Respir. Cell. Mol. Biol., 2011, 44(1), 24-33.
69. Clemens, M.J. Interferon and apoptosis. J. Interf. Cytokine Res., 2003, 23, 277-292.
70. Panaretakis, T.; Pokrovskaja, K.; Shoshan, M.C. Interferon-alpha induced apoptosis in U266 cells is associated with activation of the pro-apoptotic Bcl-2 family members Bak and Bax. Oncogene, 2003, 22, 4543-4556.
71. Stawowczyk, M.; Van Scoy, S.; Kumar, K.P.; Reich, N.C. The interferon stimulated gene 54 promotes apoptosis. J. Biol. Chem., 2010, 29, 7257-7266.
72. Uddin, S.; Majchrzak, B.; Woodson, J.; Arunkumar, P.; Alsayed, Y.; Pine, R.; Young, P.R.; Fish, E. N.; Platanias, L.C. Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem., 1999, 274, 30127-30131.
73. Goh, K.C; Haque, S.J.; Williams, B.R.G. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J., 1999, 18, 5601-5609.
74. Uddin, S.; Lekmine, F.; Sharma, N.; Majchrzak, B.; Mayer, I.; Young, P.R.; Bokoch, G.M.; Fish, E. N.; Platanias, L.C. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J. Biol. Chem., 2000, 275, 27634-27640.
75. Caraglia, M.; Abbruzzese, A.; Leardi, A.; Pepe, S.; Budillon, A.;Baldassare, G.; Selleri, C.; Lorenzo, S. D.; Fabbrocini, A.; Giuberti, G.; Vitale, G.; Lupoli, G.; Bianco, A.R.; Tagliaferri, P. Interferon- alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell. Death Differ., 1999, 6, 773-780.
76. Verma, A.; Deb, D.K.; Sassano, A.; Uddin, S.; Varga, J.; Wickrema, A.; Platanias, L.C. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J. Biol. Chem., 2002, 277, 7726-7735.
77. Mayer, I.A.; Verma, A.; Grumbach, I. M.; Uddin, S.; Lekmine, F.; Ravandi, F.; Majchrzak, B.; Fujita, S.; Fish, E.N.; Platanias, L.C. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J. Biol. Chem., 2001, 276, 28570-28577.
78. Takaoka, A.; Hayakawa, S.; Yanai, H.; Stoiber, D.; Negishi, H.; Kikuchi, H.; Sasaki, S.; Imai, K.; Shibue, T.; Honda, K.; Taniguchi, T. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature, 2003, 424, 516-523.
79. Caraglia, M.; Vitale, G.; Marra, M.; Budillon, A.; Tagliaferri, P., Abbruzzese, A. Alpha-interferon and its effects on signalling pathways within cells. Curr. Protein. Pept. Sci., 2004, 5(6), 475-85.
80. Balkwill, F.; Taylor-Papadinitriou, J. Interferon affects both G1 and S+ G2 in cells stimulated from quiescence to growth. Nature, 1978, 274, 798-800.
81. Kalvakolanu, D.V. Interferons and cell growth control. Histol. Histopathol., 2000, 15(2), 523-537.
82. Sangfelt, O.; Erickson, S.; Castro, J.; Heiden, T.; Gustafsson, A.; Einhorn, S.; Grandr, D. Molecular mechanisms underlying interferon- alpha-induced G0/G1 arrest, CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene, 1999, 18, 2798-2810.
83. Sangfelt, O.; Erickson, S.; Grandr, D. Mechanisms of interferoninduced cell cycle arrest. Front. Bioscience, 2000, 5, 479-487.
84. Subramaniam, P. S.; Cruz, P. E.; Hobeika, A. C.; Johnson, H. M. Type I interferon induction of the Cdk-inhibitor p21 WAF1 is accompanied by order G1 arrest, differentiation and apoptosis of the Daudi B-cell line. Oncogene, 1998, 16, 1885-1890.
85. Tienfenbrun, N.; Melamed, D.; Levy, N. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to reversible G0- like arrest. Mol. Cell. Biol., 1996, 16, 3934-3944.
86. Yano, H.; Iemura, A.; Haramaki, M.; Ogasawara, S.; Takayama, A.; Akiba, J.; Kojiro, M. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology, 1999, 29, 1708-1717.
87. Murphy, D.; Detjen, K.M.; Welzel, M.; Wiedenmann, B.; Rosewicz, S. Intereferon- delays S-Phase progression in human hepatocellular carcinoma cella via inhibition of specific cyclindependent kinases. Hepatology, 2001, 33, 346-356.
88. Detjen, K.M.; Welzel, M.; Farwig, K.; Brembeck, F.H.; Kaiser, A.; Riecken, E.O.; Wiedenmann, B.; Rosewicz, S. Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology, 2000, 118, 735-748.
89. Friedman, R.M.; Contente, S. Treatment of hepatitis C infections with interferon: a historical perspective. Hepat. Res. Treat., 2010, 323-326.
90. Keating, G.M. Peginterferon-a-2a (40 kD): A Review of its Use in Chronic Hepatitis B. Drugs, 2009, 69(18), 2633-2660.
91. Chen, D.S. Toward elimination and eradication of hepatitis B. J. Gastroenterol. Hepatol., 2010, 25(1), 19-25.
92. Rong, L.; Perelson, A.S. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelling. Crit. Rev. Immunol., 2010, 30(2), 131-148.
93. Friedman, R.M. Clinical uses of interferons. Br. J. Clin. Pharmacol., 2008, 65(2), 158-162.
94. Gerein, V.; Rastorguev, E.; Gerein, J.; Jecker, P.; Pfister, H. Use of interferon-alpha in recurrent repiratory papillomatosis: 20 year follow- up. Ann. Otol. Rhinol. Laryngol., 2005, 114, 463-471.
95. Scheinfeld, N.; Lehman, D.S. An evidence-based review of medical and surgical treatment of genital warts. Dermatol. Outline J., 2006, 12, 5.
96. Jonasch, E.; Haluska, F.G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist., 2001,6(1), 34-55.
97. Eggermont, A.M.; Gore, M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin. Oncol., 2007, 34(6), 509-515.
98. Garbe, C.; Peris, K.; Hauschild, A.; Saiag, P.; Middleton, M.; Spatz, A.; Grob, J.J.; Malvehy, J., Newton-Bishop, J.; Stratigos, A.; Pehamberger, H.; Eggermont, A.; Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur. J. Cancer., 2010, 46(2), 270-283.
99. Mocellin, S.; Pasquali, S.; Rossi, C.R.; Nitti, D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl. Cancer. Inst., 2010, 102(7), 493-501.
100. Sirohi, B.; Powles, R., Lawrence, D., Treleaven, J.; Kulkarni, S., Leary, A.; Rudin, C., Horton, C., Morgan. G. An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b. Ann. Oncol., 2007,18(8), 1388-1394.
101. Schaar, C.G., Kluin-Nelemans, H.C.;Marvelde, C. Interferon-a as maintenance therapy in patients with multiple myeloma. Ann. Oncol., 2005, 16, 634-639.
102. The Myeloma Trialists Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br. J. Haematol., 2001, 113, 1020-1034.
103. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 1999, 341, 1565-1571.
104. Rajkumar, S.V.; Hayman, S.; Gertz, M.A.; Dispenzieri, A., Lacy, M.Q.; Greipp, P.R.; Geyer, S.; Iturria, N., Fonseca, R.; Lust, J.A.; Kyle, R.A.; Witzig, T.E. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol., 2002, 21, 4319-4323.
105. Richardson, P.G.; Schlossman, R.L.; Weller, E.; Hideshima, T.; Mitsiades, C.; Davies, F.; LeBlanc, R.; Catley, L.P.; Doss, D.; Kelly, K.; McKenney, M.; Mechlowicz, J.; Freeman, A.; Deocampo, R.; Rich, R.; Ryoo, J.J., Chauhan, D.; Balinski, K., Zeldis, J.; Anderson, K.C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100, 3063-3067.
106. Golomb, H.M. Hairy cell leukemia: treatment successes in the past 25 years. J. Clin. Oncol., 2008, 26(16), 2607-2609.
107. Grever, M.R. How I treat hairy cell leukemia. Blood, 2010, 115(1), 21-28.
108. Dhib-Jalbut, S.; Marks, S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology, 2010, 5, 17-24.
109. Weinstock-Guttman, B., Ramanathan, M., Zivadinov, R. Interferon- treatment for relapsing multiple sclerosis. Expert Opin. Biol. Ther., 2008, 8(9), 1435-1447.
110. Polman, C.H.; OConner, P.W.; Havrdova, E., Hutchinson, M.; Kappos, L.; Miller, D.H.; Phillips, J.T.; Lublin, F.D.; Panzara, M.A., Sandrock, A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 2006, 354, 899-933.
111. Ktter, I., Hamuryudan, V.; Oztrk, Z.E.; Yazici, H. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr. Opin. Rheumatol., 2010, 22(3), 278-283.
112. Kirkwood J.M.; Bender C.; Agarwala S.; Tarhini A.; Shipe-Spotloe J.; Smelko B.; Donnelly S.; Stover L. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J. Clin. Oncol., 2002, 20(17), 3703-3718.
113. Islam M.; Frye R.F.; Richards T.J.; Sbeitan I.; Donnelly S.S.; Glue P.; Agarwala S.S.; Kirkwood J.M. Differential effect of IFNalpha- 2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin. Cancer. Res., 2002, 8(8), 2480-2487.
114. Gutterman J.U. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. USA, 1994, 91(4), 1198-1205.
115. Wills, R.J. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet.. 1990, 9(5), 390.
116. Buechner, S.; Wernli, M.; Hass, T.; Hahn, S.; Itin, P.; and Erb, P. Regression of Basal Carcinoma by Intralesional Interferon-alpha Treatment Is Mediated by CD95 (Apo-1/Fas)-CD95 Ligandinduced Suicide. J. Clin. Invest., 1997, 100, 2691-2696.
117. Bukowski, R.; Ernstoff, M.S.; Gore, M.E.; Nemunaitis, J.J.; Amato, R.; Gupta, S.K.; Tendler, C.L. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J. Clin. Oncol., 2002, 20(18), 3841-3849.
118. Bukowski, R.M.; Tendler, C.; Cutler, D.; Rose, E.; Laughlin, M.M.; Statkevich, P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferonalpha- 2b formulation. Cancer, 2002, 95(2), 389-396.
119. Motzer, R.J.; Rakhit, A.; Ginsberg, M.; Rittweger, K.; Vuky, J.; Yu, R.; Fettner, S.; Hooftman, L. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J. Clin. Oncol., 2001, 19(5), 1312-1319.
120. Yan, F.M.; Chen, A.S.; Hao, F.; Zhao, X.P.; Gu, C.H.; Zhao, L.B.; Yang, D.L.; Hao, L.J. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J. Gastroenterol., 2000, 6(6), 805-811.
121. Bruzzese, F.; Di Gennaro, E.; Avallone, A.; Pepe, S.; Arra, C.; Caraglia, M.; Tagliaferri, P.; Budillon, A. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin. Cancer Res., 2006, 12(2), 617-625.
122. Caraglia, M.; Marra, M.; Viscomi, C.; D'Alessandro, A.M.; Budillon, A.; Meo, G.; Arra, C.; Barbieri, A.; Rapp, U.R.; Baldi, A.; Tassone, P.; Venuta, S.; Abbruzzese, A.; Tagliaferri, P. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. Int. J. Cancer, 2007, 121(10), 2317-2330.
123. Caliceti, P. Pharmacokinetics of pegylated interferons: what is misleading? Dig. Liver Dis., 2004, 36(3), S334-339.
124. Yan, F.M.; Chen, A.S.; Hao, F.; Zhao, X.P.; Gu, C.H.; Zhao, L.B.; Yang, D.L.; Hao, L.J. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World. J. Gastroenterol., 2000, 6(6), 805-811.